Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

0.0%

0 terminated/withdrawn out of 45 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

24%

11 trials in Phase 3/4

Results Transparency

0%

0 of 5 completed trials have results

Key Signals

17 recruiting

Enrollment Performance

Analytics

Phase 2
17(37.8%)
Phase 1
15(33.3%)
Phase 3
11(24.4%)
Early Phase 1
2(4.4%)
45Total
Phase 2(17)
Phase 1(15)
Phase 3(11)
Early Phase 1(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (45)

Showing 20 of 45 trials
NCT07501169Phase 2Not Yet Recruiting

Sacituzumab Tirumotecan in Combination With Anlotinib in Previously Treated Patients With Extensive-Stage Small Cell Lung Cancer (ES-SCLC)

Role: collaborator

NCT07296809Phase 2Recruiting

SKB500 Combinations in Patients With Small Cell Lung Cancer

Role: lead

NCT07488065Phase 1Not Yet Recruiting

A Study of SKB575 (HBM7575) Injection in Healthy Participants and Atopic Dermatitis Participants

Role: lead

NCT06448312Phase 3Active Not Recruiting

A Study of SKB264 in Combination With Pembrolizumab Versus Pembrolizumab in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Role: lead

NCT07459998Phase 1Not Yet Recruiting

SKB103 for Injection in Advanced Solid Tumors

Role: lead

NCT07230405Phase 2Recruiting

A Phase II Study of SKB571 in Patients With Lung Cancer

Role: lead

NCT06711900Phase 3Recruiting

A Study of SKB264 in Combination With Pembrolizumab Versus Chemotherapy in Combination With Pembrolizumab as First-Line Treatment for PD-L1 Negative Patients With Locally Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer

Role: lead

NCT07380386Phase 1Not Yet Recruiting

SKB105 for Injection in Advanced Solid Tumors

Role: lead

NCT05816252Phase 2Active Not Recruiting

A Study of SKB264 (MK-2870; Sac-TMT) for the Treatment of Participants With Advanced or Metastatic Non-small Cell Lung Cancer (SKB264-II-04) (MK-2870-003)

Role: collaborator

NCT06279364Phase 3Recruiting

A Study of SKB264 Versus Investigator's Choice Chemotherapy in Patients With Unresectable Recurrent or Metastatic Triple-Negative Breast Cancer

Role: lead

NCT07348861Phase 2Not Yet Recruiting

A Phase II Study of Neoadjuvant Sacituzumab Tirumotecan in Combination With Iparomlimab and Tuvonralimab in Locally Advanced Cervical Cancer

Role: collaborator

NCT07343479Phase 2Not Yet Recruiting

Sacituzumab Tirumotecan Plus Third-Generation TKI With/Without Radiotherapy for EGFR-Mutant NSCLC Brain Metastases

Role: collaborator

NCT07341100Phase 2Not Yet Recruiting

Study to Evaluate the Preliminary Efficacy of SKB264 and the Effect of Clarithromycin on the PK of SKB264 in OC

Role: lead

NCT07329322Phase 2Not Yet Recruiting

Phase II Study of Sacituzumab Tirumotecan in Combination With Osimertinib or Sacituzumab Tirumotecan for Neoadjuvant Treatment in Patients With Resectable Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer

Role: lead

NCT07324629Phase 2Not Yet Recruiting

Sacituzumab Tirumotecan in Participants With Locally Advanced or Metastatic Thymic Carcinoma

Role: lead

NCT06725381Phase 1Recruiting

A Phase 1 Study of SKB571 in Subjects With Advanced Solid Tumors

Role: lead

NCT07308106Phase 2Not Yet Recruiting

A Phase II Clinical Study of SKB571 as Monotherapy in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer With MET Abnormalities

Role: lead

NCT07299825Phase 2Recruiting

A Study of A166 in Patients With HER2-Positive Unresectable or Metastatic Breast Cancer

Role: lead

NCT05265091Phase 1Active Not Recruiting

A Study of KL590586 in Patients With Advanced Solid Tumors

Role: lead

NCT07071337Phase 3Recruiting

A Study of SKB264 Versus Investigator's Choice of Chemotherapy in Subjects With Unresectable Locally Advanced, Relapsed, or Metastatic HR+/HER2- Breast Cancer Who Have Previously Failed Endocrine Therapy

Role: lead